None

Sigma to sell Axiogenesis' iPSC-derived cells

Sigma Life Science agreed to market Axiogenesis' mouse induced pluripotent stem cell-derived smooth muscle cells and cardiomy -More- 

USPTO approves patent for Axiogenesis’ in vitro drug discovery assay to treat HCM

The USPTO approved a patent for Axiogenesis AG for the invention of its in vitro assay to screen pharmaceutical drug candidates for effectiveness and safety in treating Hypertrophic Cardiomyopathy (HC...

Axiogenesis Earns U.S. Patent with In Vitro Drug Discovery Assay for Hypertrophic Cardiomyopathy

The USPTO approved a patent for Axiogenesis AG for the invention of its in vitro assay to screen pharmaceutical drug candidates for effectiveness and safety in treating...

Axiogenesis AG, Sigma-Aldrich sales and marketing update

Sigma Life Science and Axiogenesis Partner to Market iPS Cell-Derived Cardiomyocytes

Sigma® Life Science and Axiogenesis Collaborate to Market More Predictive iPSC-Based Assays and Services for Preclinical Cardiotoxicity Screening

ST. LOUIS, July 31, 2012 /PRNewswire/ -- Sigma-Aldrich® Corporation (Nasdaq: SIAL) today announced that Sigma Life Science, its innovative biological products and services research business, has...

None